224 related articles for article (PubMed ID: 31102204)
1. Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.
Ben-Omran T; Masana L; Kolovou G; Ariceta G; Nóvoa FJ; Lund AM; Bogsrud MP; Araujo M; Hussein O; Ibarretxe D; Sanchez-Hernández RM; Santos RD
Adv Ther; 2019 Jul; 36(7):1786-1811. PubMed ID: 31102204
[TBL] [Abstract][Full Text] [Related]
2. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
Roeters van Lennep J; Averna M; Alonso R
J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
[TBL] [Abstract][Full Text] [Related]
3. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
[TBL] [Abstract][Full Text] [Related]
4. A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting.
Blom DJ; Gaudet D; Hegele RA; Patel DS; Cegla J; Kolovou G; Marin LM
Adv Ther; 2022 Apr; 39(4):1857-1870. PubMed ID: 35194765
[TBL] [Abstract][Full Text] [Related]
5. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
Stefanutti C
Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
[TBL] [Abstract][Full Text] [Related]
6. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study.
D'Erasmo L; Steward K; Cefalù AB; Di Costanzo A; Boersma E; Bini S; Arca M; van Lennep JR;
Eur J Prev Cardiol; 2022 May; 29(5):832-841. PubMed ID: 34971394
[TBL] [Abstract][Full Text] [Related]
8. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
Cuchel M; Blom DJ; Averna MR
Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
[TBL] [Abstract][Full Text] [Related]
10. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
[TBL] [Abstract][Full Text] [Related]
11. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis.
Stefanutti C; Morozzi C; Di Giacomo S; Sovrano B; Mesce D; Grossi A
J Clin Lipidol; 2016; 10(4):782-789. PubMed ID: 27578108
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy.
D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M
Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645
[TBL] [Abstract][Full Text] [Related]
13. Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting.
Mahzari M; Zarif H
Adv Ther; 2021 May; 38(5):2159-2169. PubMed ID: 33829367
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
D'Erasmo L; Gallo A; Cefalù AB; Di Costanzo A; Saheb S; Giammanco A; Averna M; Buonaiuto A; Iannuzzo G; Fortunato G; Puja A; Montalcini T; Pavanello C; Calabresi L; Vigna GB; Bucci M; Bonomo K; Nota F; Sampietro T; Sbrana F; Suppressa P; Sabbà C; Fimiani F; Cesaro A; Calabrò P; Palmisano S; D'Addato S; Pisciotta L; Bertolini S; Bittar R; Kalmykova O; Béliard S; Carrié A; Arca M; Bruckert E
Orphanet J Rare Dis; 2021 Sep; 16(1):381. PubMed ID: 34496902
[TBL] [Abstract][Full Text] [Related]
15. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.
Blom DJ; Cuchel M; Ager M; Phillips H
Orphanet J Rare Dis; 2018 Jun; 13(1):96. PubMed ID: 29925433
[TBL] [Abstract][Full Text] [Related]
16. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.
Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AF; Stroes E; Taskinen MR; Wiegman A; Wiklund O; Chapman MJ;
Eur Heart J; 2014 Aug; 35(32):2146-57. PubMed ID: 25053660
[TBL] [Abstract][Full Text] [Related]
17. Lomitapide for the management of homozygous familial hypercholesterolemia.
deGoma EM
Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
[TBL] [Abstract][Full Text] [Related]
18. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.
Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P
J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816
[TBL] [Abstract][Full Text] [Related]
19. Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience.
Aljenedil S; Alothman L; Bélanger AM; Brown L; Lahijanian Z; Bergeron J; Couture P; Baass A; Ruel I; Brisson D; Khoury E; Gaudet D; Genest J
Atherosclerosis; 2020 Oct; 310():54-63. PubMed ID: 32906018
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study.
Nohara A; Otsubo Y; Yanagi K; Yoshida M; Ikewaki K; Harada-Shiba M; Jurecka A
J Atheroscler Thromb; 2019 Apr; 26(4):368-377. PubMed ID: 30259883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
